Mayo Leads PGx Study for Antiplatelet Medication, Genotype Testing | GenomeWeb

NEW YORK (GenomeWeb News) – Mayo Clinic is partnering with three US healthcare groups to study if prescribing heart medications based on a patient's genotype will improve outcomes in angioplasty patients, NorthShore University HealthSystem, one of the project partners, said today.

The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) study seeks to find out if testing for a patient's genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo angioplasty.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.